Home / Technology & Devices

Technology & Devices

ArcherDX Personalized Cancer Monitoring Technology Designated by FDA as Breakthrough Device

BOULDER, Colo., Jan. 14, 2020 /PRNewswire/ — ArcherDX, Inc., today announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a bespoke, minimally-invasive and highly-sensitive product intended for early-stage cancer treatment monitoring and recurrence surveillance. ArcherDX’s technology enables …

Read More »

Personal Genome Diagnostics and Eisai Partner to Develop Comprehensive Liquid Biopsy Biomarker Discovery Solution

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, is partnering with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology, to be used by Eisai researchers at their Tsukuba Research Laboratory. The goal of this collaboration is to create a kitted NGS …

Read More »

QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer

Hilden, Germany and Germantown, Maryland, January 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation. The agreement focuses initially on companion diagnostics …

Read More »

ZebiAI Therapeutics Collaborates with Google Accelerated Science to Unlock Novel Therapeutic Targets

WALTHAM, Mass.–(BUSINESS WIRE)–ZebiAI Therapeutics, Inc., a privately held company, announced a multiyear service and collaboration agreement with Google Accelerated Science (GAS) (https://research.google/teams/applied-science/gas/), Mountain View, CA, focused on the application of machine learning to accelerate the identification of small molecule therapeutics. ZebiAI Therapeutics was established to apply machine learning and DEL …

Read More »

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership announcements that further the company’s commitment to unlocking the power of the genome. Speaking today at the 38th Annual J.P. Morgan Healthcare …

Read More »

Concerto HealthAI and Pfizer Expand Collaboration to Accelerate Real-World Evidence and AI Technologies for Additional Disease Areas

BOSTON, Jan. 10, 2020 /PRNewswire/ — Concerto HealthAI announced an expansion of their existing Precision Oncology collaboration with Pfizer Oncology to advance Concerto HealthAI’s use-case engineered Real-World Data (RWD) for an array of clinical development initiatives across breast, lung, prostate and renal cell carcinoma cancers that will drive innovative new …

Read More »

Xencor and Gilead Enter License Agreement for Use of XmAb Antibody Technologies in Investigational Agents for HIV

MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology license agreement in which Gilead Sciences, Inc., will access Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for …

Read More »

Personal Genome Diagnostics and Mayo Clinic Enter Strategic Collaboration to Enhance Patient Care in Oncology

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Mayo Clinic to enhance the development of clinical diagnostic solutions for oncology. Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies for liquid biopsy and tissue-based genomic applications. The two organizations …

Read More »

Schrödinger and Bayer Collaborate to Co-Develop de novo Design Technology to Accelerate Drug Discovery

NEW YORK–(BUSINESS WIRE)–Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs. The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the …

Read More »

Personalis Launches a Comprehensive Genomic Cancer Profiling Test Enabling Advanced Composite Biomarkers for Cancer Treatment

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer diagnostic platforms to …

Read More »